| 1st Jul 2026 3:00 pm |
RNS |
Total Voting Rights |
| 29th Jun 2026 3:00 pm |
RNS |
Transaction in Own Shares |
| 29th Jun 2026 3:00 pm |
RNS |
Holding(s) in Company |
| 26th Jun 2026 3:00 pm |
RNS |
Holding(s) in Company |
| 24th Jun 2026 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 24th Jun 2026 2:52 pm |
RNS |
GSK announces tender offer to acquire Nuvalent |
| 23rd Jun 2026 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 22nd Jun 2026 3:00 pm |
RNS |
Transaction in Own Shares |
| 17th Jun 2026 4:06 pm |
RNS |
cUTI oral antibiotic Tebipenem approved by US FDA |
| 15th Jun 2026 3:00 pm |
RNS |
Transaction in Own Shares |
| 12th Jun 2026 7:00 am |
RNS |
Momelotinib orphan drug designations for VEXAS |
| 11th Jun 2026 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 10th Jun 2026 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 9th Jun 2026 5:51 pm |
RNS |
Dr Hal Barron – New Directorship |
| 9th Jun 2026 7:00 am |
RNS |
GSK enters agreement to acquire Nuvalent, Inc. |
| 8th Jun 2026 3:00 pm |
RNS |
Transaction in Own Shares |
| 1st Jun 2026 3:00 pm |
RNS |
Total Voting Rights |
| 1st Jun 2026 3:00 pm |
RNS |
Transaction in Own Shares |
| 28th May 2026 9:30 am |
RNS |
Positive Phase 3 data for bepirovirsen |
| 27th May 2026 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 26th May 2026 3:00 pm |
RNS |
Admission to Trading |
| 26th May 2026 3:00 pm |
RNS |
Transaction in Own Shares |
| 22nd May 2026 10:30 am |
RNS |
Q2 2026 Results Date Confirmed - 28 July 2026 |
| 20th May 2026 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 19th May 2026 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 18th May 2026 3:00 pm |
RNS |
Transaction in Own Shares |
| 18th May 2026 7:00 am |
RNS |
Japan MHLW approves Arexvy for adults 18-49 AIR |
| 14th May 2026 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 11th May 2026 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 11th May 2026 7:05 am |
RNS |
Collaboration with CTTQ for bepirovirsen |
| 11th May 2026 7:00 am |
RNS |
GSK - final tranche of share buyback programme |
| 6th May 2026 6:22 pm |
RNS |
Result of AGM |
| 5th May 2026 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 1st May 2026 3:00 pm |
RNS |
Holding(s) in Company |
| 1st May 2026 3:00 pm |
RNS |
Total Voting Rights |
| 29th Apr 2026 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 29th Apr 2026 7:00 am |
RNS |
1st Quarter Results |
| 28th Apr 2026 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 28th Apr 2026 7:00 am |
RNS |
Bepirovirsen priority review US filing acceptance |
| 27th Apr 2026 12:00 pm |
RNS |
Efimosfermin granted US/EU regulatory designations |
